EMA’s CHMP backs Merck’s Keytruda for first-line treatment of NSCLC
The recommendation is for treating NSCLC patients whose tumors have high PD-L1 expression without any EGFR or ALK positive tumor mutations. The CHMP’s positive opinion came through from
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.